XHKG
2779
Market cap71mUSD
Oct 09, Last price
0.34HKD
1D
-4.29%
1Q
8.06%
IPO
-89.69%
Name
China Xinhua Education Group Ltd
Chart & performance
P/E
1.36
P/S
0.70
EPS
0.21
Div yield, %
18.06%
Shrs. gr., 5y
—
Rev. gr., 5y
6.56%
Revenues
658m
+1.54%
Net income
338m
+2.37%
CFO
362m
-24.67%
Dividend
Jun 20, 20240.0632 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Xinhua Education Group Limited, together with its subsidiaries, provides higher and secondary vocational education services in the People's Republic of China. The company operates four private schools, which include Anhui Xinhua University that offers undergraduate and junior college programs focusing on engineering and management, economics, education, literature, medical studies, and arts; Clinical College of Anhui Medical University, an undergraduate university that offers a range of medical undergraduate courses, including clinical medicine, pharmacy, public affairs management, nursing, biomedical engineering, rehabilitation therapy, and medical imaging technique; Nanjing University of Finance & Economics Hongshan College; and Anhui Xinhua School, a full-time secondary vocational school. It also offers technical and management consultancy services. China Xinhua Education Group Limited was founded in 1999 and is headquartered in Hefei, China.
Key people
Junbao Wu
Non-Executive Chairman of the Board · since 2017
Yongkai Wang
Executive President, Executive Director · since 2017
Yuan Huang
Vice President · since 2015
Ming Chen
Executive Director · since 2024
Ming Zhang
Executive Director · since 2018
Zheng Ni
Chief Officer of International Operations · since 2017
Jihong Wang
Chief Strategy Officer · since 2017
Company Secretary · since 2022
Min Jiang
Independent Non-Executive Director · since 2019
Zhanjun Yang
Independent Non-Executive Director · since 2017
Independent Non-Executive Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||